3hon MSN
Nebraska Hematology Oncology becomes state’s only trial site for new prostate cancer treatment
The treatment, called Pasritamig, teaches the immune system's T cells to target and attack cancer cells in the prostate.
A urologist explains the options and warns that ignoring an enlarged prostate could lead to permanent bladder damage.
Morning Overview on MSN
Capivasertib won FDA approval for a hard-to-treat form of prostate cancer
Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results